STOCK TITAN

Renalytix plc American Depositary Shares SEC Filings

RNLX NASDAQ

Welcome to our dedicated page for Renalytix plc American Depositary Shares SEC filings (Ticker: RNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Trying to follow every FDA update, payor-coverage detail, and algorithm performance metric hidden in Renalytix’s SEC paperwork can feel like decoding a clinical trial protocol. The company’s biotech disclosures run deep—lab certifications, KidneyIntelX adoption data, and reimbursement assumptions are scattered across hundreds of pages. That’s why we start with the problem: Renalytix filings are technically rich and time-consuming to read.

Stock Titan’s AI-powered analysis transforms those documents into clear takeaways. Open the Renalytix quarterly earnings report 10-Q filing and our system highlights test-volume trends in seconds. Need to monitor Renalytix insider trading Form 4 transactions? Real-time alerts surface every executive stock move, while the phrase “Renalytix Form 4 insider transactions real-time” leads you straight to the data. We also decode risk factors in the Renalytix annual report 10-K simplified, flagging FDA milestones, CLIA lab costs, and revenue concentration so you can focus on decisions—not page counts.

From Renalytix 8-K material events explained (think sudden FDA feedback) to the Renalytix proxy statement executive compensation, every filing type is covered and updated the moment it hits EDGAR. Use our platform to:

  • Track reimbursement commentary buried in management discussion sections
  • Compare quarter-over-quarter cash burn without spreadsheet gymnastics
  • Set alerts for “Renalytix earnings report filing analysis” and “understanding Renalytix SEC documents with AI” so you never miss a development

Whether you follow diagnostic test adoption curves or simply want confidence that you’ve captured each Renalytix executive stock transactions Form 4, this page turns complex biotech filings into actionable insight—no scientific degree required.

Rhea-AI Summary

Renalytix plc (RNLX) filed Post-Effective Amendment No. 1 to its Form S-8 (Reg. No. 333-274732). The amendment terminates the effectiveness of the original registration statement and dere­gisters all ordinary shares (£0.0025 par value) that remain unissued under two employee programs: (1) the 2020 Employee Share Purchase Plan and (2) the 2020 Equity Incentive Plan. No new securities will be offered pursuant to these plans under this registration after the filing becomes effective, which occurs automatically upon submission under Rule 464.

The company confirms its status as a non-accelerated filer, smaller reporting company, and emerging growth company. The document is signed by CEO James McCullough in London on 25 July 2025, with no additional signatures required under Rule 478.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Renalytix plc (RNLX) filed Post-Effective Amendment No. 1 to its Form S-8 (Reg. No. 333-274732). The amendment terminates the effectiveness of the original registration statement and dere­gisters all ordinary shares (£0.0025 par value) that remain unissued under two employee programs: (1) the 2020 Employee Share Purchase Plan and (2) the 2020 Equity Incentive Plan. No new securities will be offered pursuant to these plans under this registration after the filing becomes effective, which occurs automatically upon submission under Rule 464.

The company confirms its status as a non-accelerated filer, smaller reporting company, and emerging growth company. The document is signed by CEO James McCullough in London on 25 July 2025, with no additional signatures required under Rule 478.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Renalytix plc American Depositary Shares (RNLX)?

The current stock price of Renalytix plc American Depositary Shares (RNLX) is $0.2071 as of February 7, 2025.

What is the market cap of Renalytix plc American Depositary Shares (RNLX)?

The market cap of Renalytix plc American Depositary Shares (RNLX) is approximately 17.2M.

What is Renalytix plc's core business focus?

Renalytix plc focuses on developing AI-powered diagnostic solutions aimed at improving the early detection and management of kidney disease. Its innovative approach integrates advanced machine learning with clinical data to enhance patient stratification and clinical outcomes.

How does the company utilize artificial intelligence in its diagnostic solutions?

The company employs advanced AI and machine learning algorithms to interpret complex clinical data, thereby accelerating the diagnostic process and improving accuracy. This integration allows for rapid, data-driven insights that support efficient clinical decision-making.

Who are the primary beneficiaries of Renalytix plc’s technology?

The primary beneficiaries include healthcare providers, laboratory professionals, and pharmaceutical companies involved in clinical research. Additionally, patients with chronic kidney disease or at high risk of developing the condition benefit from earlier and more precise diagnostic assessments.

What differentiates Renalytix plc from traditional diagnostic companies?

Renalytix plc stands out due to its deep integration of AI within its diagnostic process, which enhances speed and accuracy beyond conventional methods. Its emphasis on clinical validation, regulatory compliance, and incorporation of real-world outcomes further solidifies its competitive edge.

How does the company ensure the reliability of its diagnostic tests?

The company employs rigorous clinical validation studies and continuously integrates real-world data to ensure high reliability. Compliance with regulatory standards and inclusion in clinical guidelines further underlines the reliability and robustness of its tests.

What role does the company’s flagship test play in kidney disease management?

The flagship diagnostic test is central to the company’s mission of transforming kidney care. It is used for early detection, risk stratification, and aiding in clinical decision-making, which ultimately helps improve patient outcomes and reduce healthcare costs.

How does Renalytix plc generate its revenue?

The company generates revenue through its laboratory-developed tests, offered to health systems, research institutions, and pharmaceutical companies. Its scalable business model focuses on direct laboratory testing services and strategic partnerships within the healthcare ecosystem.

What is the competitive landscape for Renalytix plc in the healthcare diagnostics sector?

Renalytix plc operates in a competitive field where traditional diagnostics and emerging digital health technologies often intersect. Its distinctive integration of AI with clinical diagnostics, along with strong regulatory and clinical validations, helps it maintain a unique position in the evolving market.
Renalytix plc American Depositary Shares

NASDAQ:RNLX

RNLX Rankings

RNLX Stock Data

17.18M
165.93M
4.51%
4.14%
0.46%
Health Information Services
Services-medical Laboratories
Link
United States
LONDON